Although TCGA analysis revealed that TRIM47 was highly expressed in ovarian cancer, additional prospective clinical trials with a large population are still warranted to validate the upregulation of TRIM47 in ovarian cancer and evaluate its clinical significance. This evidence concerns the gene TRIM47 and ovarian carcinoma.